Recent

% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • biotuesday biotuesday May 14, 2013 8:24 AM Flag

    This week's BioTuesdays feature - Galena to target Abstral as market leader for cancer pain

    Galena Biopharma (NASDAQ:GALE) plans to make its recently acquired Abstral sublingual tablets the market leader for the treatment of breakthrough cancer pain (BTcP) in the U.S., matching the product’s performance in Europe.

    “Abstral is the latest and best-in-class drug for this indication,” president and CEO Mark Ahn says in an interview with BioTuesdays, noting that the company is on track for a fourth quarter launch...

    See BT for rest of article

 
GALE
1.55+0.04(+2.65%)2:27 PMEDT